- Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Most popular

All articles

Show search box
Avastin – chance in cancer treatment

Avastin – chance in cancer treatment

European Commission (EC) approved the bevacizumab (Avastin) as a medication in treating recurrent ovarian cancer resistant to chemotherapy containing platinum. Avastin has to be combined with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy.... Read more
Tags cancer , Avastin , cancer therapy , ovarian cancer